DURHAM, N.C., August 18, 2026
Humacyte, Inc. announced that its FDA-approved bioengineered blood vessel Symvess® has entered commercial use in Arizona, marking another step in the adoption of bioengineered human tissue technology in vascular surgery. Jeromy Brink, MD, a board-certified vascular and endovascular surgeon in Phoenix, has performed four Symvess implantations at Banner University Medical Center since gaining access to the product approximately two weeks ago. The Arizona procedures represent early commercial utilization of Symvess following its FDA approval for adults with extremity arterial injuries requiring urgent revascularization when an autologous vein graft is not feasible. The availability of an off-the-shelf vascular conduit is particularly relevant in emergency surgical settings, where conventional vein harvesting can require additional operative time and create a second surgical site. Humacyte is positioning Symvess as a new option for hospitals and vascular surgeons managing patients facing potential limb loss.
Symvess Expands Commercial Availability in Vascular Surgery
The commercial use of Symvess highlights the practical importance of having an immediately available vascular conduit in urgent procedures. Unlike autologous grafting, which requires surgeons to harvest a suitable vein from the patient, Symvess is designed to be available off-the-shelf in the operating room. Humacyte describes the product as an acellular tissue-engineered vessel developed from bioengineered human tissue. For patients with severe extremity arterial injury, rapid restoration of blood flow can be critical to preventing limb loss. The ability to access a vascular conduit without first performing a separate vein-harvesting procedure may help streamline the surgical workflow and reduce the need for an additional surgical site. Dr. Brink, who trained at Mayo Clinic and has practiced vascular surgery for 25 years, described Symvess as a significant advancement in open surgical bypass based on his initial clinical experience. Humacyte emphasized that individual surgeon experiences may vary and that Symvess is currently approved specifically for its vascular trauma indication.
Bioengineered Blood Vessel Addresses Unmet Surgical Need
The commercial rollout of Symvess represents a broader development in regenerative medicine and tissue engineering, as Humacyte works to establish bioengineered human tissues as practical medical products. Symvess received FDA approval in December 2024 for use as a vascular conduit in adults with extremity arterial injury when urgent revascularization is required and an autologous vein graft is not feasible. Its off-the-shelf availability differentiates it from conventional approaches that depend on suitable patient-derived tissue. Humacyte is also evaluating its vascular tissue technology in additional clinical applications, including arteriovenous access for hemodialysis and peripheral artery disease. These programs could potentially expand the role of bioengineered vascular conduits beyond emergency trauma care if supported by clinical evidence and regulatory approvals. The company is therefore using the commercial launch of Symvess not only to establish adoption in vascular trauma but also to demonstrate the broader potential of its tissue-engineering platform across vascular medicine.
Advertisement
Humacyte Builds Commercial Platform Around Tissue Engineering
Beyond the initial Symvess commercialization, Humacyte is developing a broader portfolio of bioengineered human tissues designed to address diseases, injuries and chronic conditions. The company’s technology focuses on producing acellular tissue constructs that can potentially be implanted without requiring patient-specific tissue harvesting. Its vascular programs include a 6 mm bioengineered vessel for hemodialysis access, which has received FDA Regenerative Medicine Advanced Therapy and Fast Track designations, as well as programs targeting peripheral artery disease and other vascular applications. Humacyte is also pursuing preclinical research in areas including coronary artery bypass grafting, pediatric heart surgery, type 1 diabetes and other cell and tissue applications. The commercial use of Symvess in Arizona provides an important real-world milestone for the company as it moves from clinical development toward broader utilization of bioengineered tissue products. For the medical technology sector, the development demonstrates how tissue engineering, regenerative medicine and advanced biomaterials are increasingly moving toward practical applications in complex surgical care.
Source: Humacyte press relese
